THE SCIENCE
Our Approach
Our team of proven drug developers is simultaneously advancing therapeutic approaches blocking the B7-H7 immune signaling pathway and utilizing the unique upregulation of B7-H7 in cancer as an anchor for tumor-targeting treatment modalities.
EXCITING NEW TARGET
Our Founders Independently Discovered a Novel B7 Receptor Checkpoint Axis
- Clinical opportunities independent of established immunotherapies
- Broad pipeline maximizing opportunities for immunomodulation and tumor-targeting through B7-H7
- All first-in-class assets with a strong IP position
STRATEGY
Targeting A Novel Immuno-Oncology Checkpoint and Tumor-Associated Antigen
Our Pipeline
Broad pipeline maximizing opportunities for immunomodulation and tumor-targeting by exploiting all aspects of the B7-H7 axis
Discovery
|
Ab Development
|
DC Selection
|
Manufacturing
|
GLPtox/IND
|
Clinical
|
---|
Discovery
|
Clinical
|
---|
ABOUT US
One pathway, many possibilities
First-in-class opportunity
NextPoint is launching a new world of immuno-oncology and tumor-targeting through its leading scientific work on the novel B7-H7/HHLA2 pathway.
Attractive Monotherapies
Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients including those who do not benefit from PD-1/L1 inhibitors.
Precision oncology
OUR TEAM
World-class team
We are building a world-class team to help us realize the full potential of our scientific founders’ exciting discoveries and to shape the future of immuno-oncology and tumor-targeting
![Ivan Cheung, MBA, Chief Executive Officer, Headshot](https://nextpointtx.com/wp-content/uploads/2024/03/Ivan-Cheung.jpg)
Ivan Cheung, MBA
Chief Executive Officer
![Paul Conrad, PhD, MBA, Chief Business Officer, Headshot](https://nextpointtx.com/wp-content/uploads/2024/03/Paul-Conrad.jpg)
Paul Conrad, PhD, MBA
Chief Business Officer
![Leena Gandhi, MD, PhD, Chief Medical Officer, Headshot](https://nextpointtx.com/wp-content/uploads/2024/03/Leena-Gandhi.jpg)
Leena Gandhi, MD, PhD
Chief Medical Officer
![Tatiana Novobrantseva, PhD, Chief Scientific Officer, Headshot](https://nextpointtx.com/wp-content/uploads/2024/03/Tatiana-Novobrantseva.jpg)
Tatiana Novobrantseva, PhD
Chief Scientific Officer
![Gordon Freeman, Ph.D.](https://nextpointtx.com/wp-content/uploads/2024/03/Freeman-headshot.jpg)
Gordon Freeman, PhD
Dana-Farber Cancer Institute
![Xingxing Zang](https://nextpointtx.com/wp-content/uploads/2024/03/Xingxing-Zang-1.jpg)
XingXing Zang, PhD
Albert Einstein College of Medicine
QUOTES FROM
OUR FOUNDERS
The combined expertise and research of Gordon Freeman, PhD (Dana-Farber Cancer Institute) and XingXing Zang, PhD (Albert Einstein College of Medicine) form the basis of NextPoint Therapeutics. We are building a world-class team to help us realize the full potential of their exciting discoveries and to shape the future of immuno-oncology and tumor targeting.
![Gordon Freeman, Ph.D.](https://nextpointtx.com/wp-content/uploads/2024/03/Freeman-headshot.jpg)
I’m fascinated by the HHLA2 pathway because it looks like an alternative, non-redundant pathway than PD-L1 for turning off the anti-tumor immune response. I want Nextpoint to test whether it can be as effective as blocking PD-L1. Can we catch lightning twice?
- Gordon Freeman, PhD
![Xingxing Zang](https://nextpointtx.com/wp-content/uploads/2024/03/Xingxing-Zang-1.jpg)
From the discovery of the HHLA2 immune checkpoint pathway in 2013 to the first-in-class clinical trial targeting this pathway in 2023, NextPoint Therapeutics is revolutionizing the landscape of immuno-oncology and offering new hope for a broad spectrum of human cancer patients unresponsive to existing PD-1/L1 inhibitors.
- XingXing Zang, PhD
Investors & partners
We’re proud to collaborate with visionary investors and esteemed partners who share our commitment to advancing the field of precision immuno-oncology and tumor-targeting therapeutics
![MPM BioImpact](https://nextpointtx.com/wp-content/uploads/2024/04/Logo_mpm.png)
![Leaps Logo](https://nextpointtx.com/wp-content/uploads/2024/04/Logo_leaps-1.png)
![Sanofi Logo](https://nextpointtx.com/wp-content/uploads/2024/04/Logo_sanofi.png)
![Catalio Logo](https://nextpointtx.com/wp-content/uploads/2024/04/Logo_catalio.png)
![Dana Farber](https://nextpointtx.com/wp-content/uploads/2024/05/Binney-Street-color-logo-grey-lettering.png)
![Simcere Logo](https://nextpointtx.com/wp-content/uploads/2024/04/Logo_simcere.png)
![Logo_sixty degree](https://nextpointtx.com/wp-content/uploads/2024/04/Logo_sixty-degree-1.png)
![Pagoda Tree Partners](https://nextpointtx.com/wp-content/uploads/2024/04/Logo_pagodatree.png)
![Invus Logo](https://nextpointtx.com/wp-content/uploads/2024/04/Logo_invus-5.png)
![Arkin Bio Logo](https://nextpointtx.com/wp-content/uploads/2024/04/Logo_arkin-bio-5.png)
News & Publications
Careers
Join us at NextPoint Therapeutics and be part of a team pioneering immuno-oncology advancements
Check out the open positions on our LinkedIn
Send us an email with your resume
![Careers-Arrow-sm Careers-Arrow-sm](https://nextpointtx.com/wp-content/uploads/2023/10/Careers-Arrow-sm.png)